Latest Articles
Utepreva launches FDA-cleared endometrial sampler to support endometrial cancer detection - Contemporary OB/GYN
Utepreva launches FDA-cleared endometrial sampler to support endometrial cancer detection Contemporary OB/GYN
Published: April 22, 2026, 9:05 p.m.
Mo-Rez shows strong early responses in ovarian, endometrial cancers - Rare Cancer News
Mo-Rez shows strong early responses in ovarian, endometrial cancers Rare Cancer News
Published: April 22, 2026, 4:40 p.m.
Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort - Via Medica Journals
Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort Via Medica Journals
Published: April 22, 2026, 2:34 p.m.
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer - PR Newswire
Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer PR Newswire
Published: April 22, 2026, 2:08 p.m.
BioNTech (BNTX) Is Up 13.4% After Positive HER2 Endometrial Cancer Phase 2 Data Release - simplywall.st
BioNTech (BNTX) Is Up 13.4% After Positive HER2 Endometrial Cancer Phase 2 Data Release simplywall.st
Published: April 22, 2026, 11:30 a.m.
FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer - EMJ
FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer EMJ
Published: April 21, 2026, 3:59 a.m.
JAMA Review by Roswell Park Experts Details Rising Endometrial Cancer Rates, Impact of New Precision Treatments | Newswise - Newswise
JAMA Review by Roswell Park Experts Details Rising Endometrial Cancer Rates, Impact of New Precision Treatments | Newswise Newswise
Published: April 21, 2026, 1:10 a.m.
JAMA Review by Roswell Park Experts Details Rising Endometrial Cancer Rates, Impact of New Precision Treatments - Roswell Park Comprehensive Cancer Center
JAMA Review by Roswell Park Experts Details Rising Endometrial Cancer Rates, Impact of New Precision Treatments Roswell Park Comprehensive Cancer Center
Published: April 20, 2026, 1 p.m.
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer Oncodaily
Published: April 18, 2026, 6:23 p.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times
Published: April 17, 2026, 12:30 p.m.
Link copied to clipboard!